What changed: Localised prostate cancer, high and very high risk
Every dated change on the records linked to Localised prostate cancer, high and very high risk, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Trial result5Milestone4This record1
September 2026 · 1
2023 · 2
- 2023Trial resultLIGHTHOUSELIGHTHOUSE reported
Specificity for pelvic lymph node metastases met the pre-specified threshold (93-97% across readers) but sensitivity did not (23-30%); the agent additionally identified distant (M1) lesions, later verified true-positive in 10-15% of men (Eur Urol 2023; ASCO GU 2023)
- 2023Trial resultLuTectomyLuTectomy reported
A single dose of neoadjuvant 177Lu-PSMA-617 delivered a median tumour absorbed dose of 35.